| Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial D Tripathy, SA Im, M Colleoni, F Franke, A Bardia, N Harbeck, SA Hurvitz, ... The lancet oncology 19 (7), 904-915, 2018 | 899 | 2018 |
| Overall survival with ribociclib plus endocrine therapy in breast cancer SA Im, YS Lu, A Bardia, N Harbeck, M Colleoni, F Franke, L Chow, J Sohn, ... New England journal of medicine 381 (4), 307-316, 2019 | 898 | 2019 |
| Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2− Advanced … YS Lu, SA Im, M Colleoni, F Franke, A Bardia, F Cardoso, N Harbeck, ... Clinical Cancer Research 28 (5), 851-859, 2022 | 118 | 2022 |
| Phase III MONALEESA-7 trial of premenopausal patients with HR+/HER2− advanced breast cancer (ABC) treated with endocrine therapy±ribociclib: Overall survival (OS) results. SA Hurvitz, SA Im, YS Lu, M Colleoni, FA Franke, A Bardia, N Harbeck, ... Journal of Clinical Oncology 37 (18_suppl), LBA1008-LBA1008, 2019 | 46 | 2019 |
| First-line ribociclib vs placebo with goserelin and tamoxifen or a non-steroidal aromatase inhibitor in premenopausal women with hormone receptor-positive, HER2-negative … D Tripathy, J Sohn, SA Im, M Colleoni, F Franke, A Bardia, N Harbeck, ... Cancer Research 78 (4), 2018 | 44 | 2018 |
| Abstract PD2-04: Updated overall survival (OS) results from the phase III MONALEESA-7 trial of pre-or perimenopausal patients with hormone receptor positive/human epidermal … D Tripathy, SA Im, M Colleoni, F Franke, A Bardia, N Harbeck, S Hurvitz, ... Cancer Research 81 (4_Supplement), PD2-04-PD2-04, 2021 | 38 | 2021 |
| Genomic profiling of premenopausal HR+ and HER2–metastatic breast cancer by circulating tumor DNA and association of genetic alterations with therapeutic response to endocrine … A Bardia, F Su, N Solovieff, SA Im, J Sohn, KS Lee, S Campos-Gomez, ... JCO precision oncology 5, 1408-1420, 2021 | 25 | 2021 |
| Lung cancer in Mexico O Arrieta, ZL Zatarain-Barrón, F Aldaco, F Barrón, R Báez-Saldaña, ... Journal of Thoracic Oncology 14 (10), 1695-1700, 2019 | 23 | 2019 |
| Prevalence trends of wood use as the main cooking fuel in Mexico, 1990-2013 E Hernández-Garduño, E Gómez-García, S Campos-Gómez salud pública de méxico 59, 68-75, 2017 | 20 | 2017 |
| Inulin supplementation reduces systolic blood pressure in women with breast cancer undergoing neoadjuvant chemotherapy Y Becerril-Alarcón, S Campos-Gómez, JJ Valdez-Andrade, ... Cardiovascular therapeutics 2019, 2019 | 19 | 2019 |
| National Clinical Practice Guidelines for the management of non-small cell lung cancer in early, locally advanced and metastatic stages. Extended version. F Barrón-Barrón, E Guzmán-De Alba, J Alatorre-Alexander, ... Salud publica de Mexico 61 (3), 359-414, 2019 | 19 | 2019 |
| Guía de Práctica Clínica Nacional para el manejo del cáncer de pulmón de células no pequeñas en estadios tempranos, localmente avanzados y metastásicos F Barrón-Barrón, E Guzmán-De Alba, J Alatorre-Alexander, ... salud pública de méxico 61 (3, may-jun), 359-414, 2019 | 17 | 2019 |
| Characteristics and long‐term outcomes of advanced pleural mesothelioma in Latin America (MeSO‐CLICaP) L Rojas, AF Cardona, R Trejo‐Rosales, ZL Zatarain‐Barrón, ... Thoracic Cancer 10 (3), 508-518, 2019 | 14 | 2019 |
| Abstract GS2-05: First-line ribociclib vs placebo with goserelin and tamoxifen or a non-steroidal aromatase inhibitor in premenopausal women with hormone receptor-positive … D Tripathy, J Sohn, SA Im, M Colleoni, F Franke, A Bardia, N Harbeck, ... Cancer Research 78 (4_Supplement), GS2-05-GS2-05, 2018 | 13 | 2018 |
| Lung adenocarcinoma with concurrent KRAS mutation and ALK rearrangement responding to crizotinib: case report S Campos-Gomez, H Lara-Guerra, MJ Routbort, X Lu, GR Simon The International Journal of Biological Markers 30 (2), 254-257, 2015 | 13 | 2015 |
| Ribociclib treatment benefit in patients with advanced breast cancer with>= 1 dose reduction: Data from the MONALEESA-2,-3, and-7 trials JT Beck, P Neven, J Sohn, A Chan, GS Sonke, T Bachelot, ... CANCER RESEARCH 79 (4), 2019 | 11 | 2019 |
| Case report: anti-hormonal therapy in the treatment of ductal carcinoma of the parotid gland S Campos-Gómez, JH Flores-Arredondo, R Dorantes-Heredia, ... BMC cancer 14, 1-4, 2014 | 11 | 2014 |
| In-depth gene expression analysis of premenopausal patients with HR+/HER2− advanced breast cancer (ABC) treated with ribociclib-containing therapy in the Phase III MONALEESA-7 … YS Lu, SA Hurvitz, F Su, W He, D Tripathy, S Campos Gomez, KH Jung, ... Journal of Clinical Oncology 37 (15_suppl), 1018-1018, 2019 | 7 | 2019 |
| Brigatinib in ALK-positive non-small cell lung cancer: real-world data in the Latin American population (Bri-world extend CLICaP) D Heredia, F Barrón, AF Cardona, S Campos, J Rodriguez-Cid, ... Future Oncology 17 (2), 169-181, 2020 | 6 | 2020 |
| DE MÉXICO S T E S I UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO, 2013 | 6 | 2013 |
Debu TripathyProfessor of Breast Medical Oncology, MD Anderson Cancer CenterVerified email at mdanderson.org
